Pomegra
Cambridge biotech secures $188 million in an oversubscribed Series E to advance LIFE-001, a fungi-derived alternative to the nephrotoxic immunosuppressants that have defined organ transplantation for four decades.
- LifeMine Therapeutics closed a $188M Series E led by Milky Way Investments, with Bezos Expeditions, Gates Frontier, and RA Capital among new backers.
- LIFE-001 showed no clinically meaningful renal, metabolic, or cardiovascular signals in a Phase 1 study of more than 120 participants.
- Phase 2 kidney and Phase 1b islet cell transplant trials are targeted to begin in early 2027.
Lead
LifeMine Therapeutics disclosed $263 million in combined financing on August 6, 2026 - a $75 million Series D that closed in Q4 2025, followed by an oversubscribed $188 million Series E. The Cambridge, Massachusetts company is using the capital to push its lead drug, LIFE-001, through late-stage clinical trials aimed at replacing the immunosuppressants that have protected transplanted organs since cyclosporine first reached patients in the 1980s. The round was led by Milky Way Investments, whose managing partner, Rick Klausner, is also LifeMine's co-founder and chairman - a dual role that signals deep conviction about the asset and raises natural questions about governance.
What Is LIFE-001, and How Does It Work?
LIFE-001 is a first-in-class calcineurin activation inhibitor - the company's term for a drug that directly blocks calcineurin, an enzyme at the center of the immune response that triggers organ rejection. The distinction matters. Every existing drug in the calcineurin inhibitor class, from tacrolimus to cyclosporin to voclosporin, works by binding intermediary proteins called immunophilins, which then suppress calcineurin indirectly. LIFE-001 bypasses those chaperones entirely and binds calcineurin at a structural site that was not previously characterized in the literature.
The drug was discovered through LifeMine's Avatar-Rx platform, which deploys machine learning and high-throughput genomics to mine the fungal biosphere for naturally occurring small molecules - what the company calls Genetically Encoded Small Molecules, or GEMs. LIFE-001 is delivered as a long-acting injectable, a formulation that sidesteps the erratic absorption issues that complicate oral tacrolimus dosing.
Why Do Existing Drugs Fall Short?
The irony of the current standard of care is structural. Tacrolimus prevents the immune system from attacking a transplanted kidney but also damages the kidney - the very organ the drug is supposed to protect. Long-term nephrotoxicity is the primary reason transplanted kidneys fail after the first year. Cardiovascular effects and neurotoxicity add to the burden. Patients typically face a lifetime of dose titration, monitoring, and side-effect management, and many still progress to chronic rejection despite treatment.
In LifeMine's ongoing Phase 1 single and multiple ascending dose study, which has enrolled more than 120 adult participants, LIFE-001 has so far produced no clinically meaningful renal, metabolic, or cardiovascular signals. Early tolerability data of that kind, while not conclusive, is what draws attention from investors who track transplantation closely: the existing market is large, the unmet need is genuine, and any drug with a cleaner safety profile has a credible commercial argument.
What Does the Investor List Signal?
The presence of Bezos Expeditions and Gates Frontier alongside specialist life-science firms like RA Capital Management, ARCH Venture Partners, GV, and Invus reflects a pattern that has become familiar in high-conviction biotech rounds: generalist capital from tech-world principals moving into areas where the biology is differentiated enough to warrant patient-capital timelines. GlaxoSmithKline is also a returning investor - the two companies established a drug discovery and development alliance in March 2022 - which keeps a major pharmaceutical buyer structurally close to the asset. Valuation was not disclosed.
Outlook
LifeMine heads into the second half of 2026 with $263 million in fresh capital, a Phase 1 dataset it has characterized as best-in-class, and a direct path to Phase 2 trials. The kidney transplant Phase 2 and an islet cell transplant Phase 1b - relevant to Type 1 diabetes patients receiving pancreatic islet transplants - are both targeted for early 2027. The company's broader thesis, that fungi represent an underexplored source of structurally novel drugs, will face its most rigorous test in those studies. LIFE-001's Phase 1 safety profile has earned the next set of questions. Whether it earns the answers is a different matter.
